Article Versions Notes

Tsai H-L, Huang C-W, Chen Y-C, Su W-C, Chang T-K, Chen P-J, Li C-C, Chang Y-T, Wang J-Y. Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in BRAF^V600E-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single-Center Observational Study. Medicina. 2023; 59(12):2108. https://doi.org/10.3390/medicina59122108

Tsai, Hsiang-Lin, Ching-Wen Huang, Yen-Cheng Chen, Wei-Chih Su, Tsung-Kun Chang, Po-Jung Chen, Ching-Chun Li, Yu-Tang Chang, and Jaw-Yuan Wang. 2023. "Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in BRAF^V600E-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single-Center Observational Study" Medicina 59, no. 12: 2108. https://doi.org/10.3390/medicina59122108

Tsai, H.-L., Huang, C.-W., Chen, Y.-C., Su, W.-C., Chang, T.-K., Chen, P.-J., Li, C.-C., Chang, Y.-T., & Wang, J.-Y. (2023). Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in BRAF^V600E-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single-Center Observational Study. Medicina, 59(12), 2108. https://doi.org/10.3390/medicina59122108